PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22687551-4	2012	Our experimental data showed that pretreatment with ATZ significantly decreased CCl(4)-induced elevation of serum aspartate transaminase (AST) and alanine transaminase (ALT) and improved hepatic histopathological abnormality.	Amitrole	52-55	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	114-136	
23941578-7	2014	RESULTS: Our experimental data showed that treatment with ATZ significantly enhanced LPS/D-Gal-induced elevation of serum aspartate transaminase (AST) and alanine transaminase (ALT), exacerbated the hepatic histopathological abnormality and decreased the survival rate of experimental animals.	Amitrole	58-61	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	122-144	
23941578-7	2014	RESULTS: Our experimental data showed that treatment with ATZ significantly enhanced LPS/D-Gal-induced elevation of serum aspartate transaminase (AST) and alanine transaminase (ALT), exacerbated the hepatic histopathological abnormality and decreased the survival rate of experimental animals.	Amitrole	58-61	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	146-149	
22687551-7	2012	In addition, posttreatment with ATZ also decreased the level of ALT and AST.	Amitrole	32-35	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	72-75	
22687551-4	2012	Our experimental data showed that pretreatment with ATZ significantly decreased CCl(4)-induced elevation of serum aspartate transaminase (AST) and alanine transaminase (ALT) and improved hepatic histopathological abnormality.	Amitrole	52-55	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	138-141